Related Experiment Video

Updated: May 12, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Distribution of hepatitis C virus genotypes in Iranian chronic infected patients

Fatemeh Jahanbakhsh Sefidi1, Hossein Keyvani, Seyed Hamidreza Monavari

  • 1Department of Virology, Tehran University of Medical Sciences, Tehran, IR Iran.

Hepatitis Monthly
|April 4, 2013
PubMed

Insights

Hepatitis C virus (HCV) genotype 1a is most common in Iran, followed by genotype 3a. Identifying HCV genotypes is crucial for effective antiviral treatment strategies.

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Hepatitis C virus (HCV) exhibits diverse global genotypes.
  • Accurate HCV genotyping is essential for guiding antiviral therapy selection.

Purpose of the Study:

  • To determine the distribution of HCV genotypes in a large Iranian patient cohort.
  • To inform regional treatment strategies based on prevalent HCV subtypes.

Main Methods:

  • Analysis of 11,561 chronic HCV patients from March 2003 to December 2011.
  • HCV RNA detection via reverse transcriptase-nested PCR.
  • Genotyping performed using restriction fragment length polymorphism (RFLP).

Main Results:

  • HCV genotype 1a was most frequent (44.9%), followed by 3a (39.6%) and 1b (11.3%).
  • Mixed HCV genotypes occurred in 2.5% of cases.
  • Genotype 1a predominated in patients over 40, while genotype 3a was more common in those under 40.

Conclusions:

  • Hepatitis C virus genotype 1a is the dominant subtype in the studied Iranian population.
  • Subtype 3a is the second most prevalent HCV genotype in Iran.
Abstract

Keywords:
GenotypeHepatitis CIran

More Related Videos

Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection11:14

Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection

Published on: November 7, 2018

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...